Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History MOLN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics MOLN

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Molecular Partners AG ADR

MOLN
Current price
3.58 USD -0.32 USD (-8.21%)
Last closed 3.89 USD
ISIN US60853G1067
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 140 860 976 USD
Yield for 12 month -50.21 %
1Y
3Y
5Y
10Y
15Y
MOLN
21.11.2021 - 28.11.2021

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease. In addition, the company develops MP0621, a molecular partners' first Switch-DARPin program, which is in preclinical trial designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation (HSCT); and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland. Address: Wagistrasse 14, Schlieren, Switzerland, 8952

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

10.75 USD

P/E ratio

Dividend Yield

Financials MOLN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures MOLN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+6 077 251 USD

Last Year

+8 605 974 USD

Current Quarter

Last Quarter

Current Year

+6 077 251 USD

Last Year

-49 897 041 USD

Current Quarter

Last Quarter

EBITDA -60 229 000 USD
Operating Margin TTM -1 231.73 %
Price to Earnings
Return On Assets TTM -21.44 %
PEG Ratio
Return On Equity TTM -33.98 %
Wall Street Target Price 10.75 USD
Revenue TTM 4 970 000 USD
Book Value 3.84 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100.00 %
Dividend Yield
Gross Profit TTM -42 534 000 USD
Earnings per share -2.09 USD
Diluted Eps TTM -2.09 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation MOLN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 1.78
Enterprise Value Revenue 3.81
Price Sales TTM 28.34
Enterprise Value EBITDA 1.23
Price Book MRQ 0.89

Technical indicators MOLN

For 52 weeks

3.36 USD 12.22 USD
50 Day MA 3.88 USD
Shares Short Prior Month 46 160
200 Day MA 4.82 USD
Short Ratio 2.10
Shares Short 39 775
Short Percent 0.29 %